Skip to content

Effectiveness of Hypertonic saline nasal irrigation and gargling in COVID-19

Effectiveness of Hypertonic saline nasal irrigation and gargling in COVID-19 patients - A randomised controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030236
Enrollment
96
Registered
2021-01-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: 1.5% to 3% Saline nasal irrigation and gargling: saline nasal irrigation and gargling minimum of 3 times to maximum of 10 times daily for 7 days or till asymptomatic whichever is earlie

Sponsors

V M Hemlata Katiyar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults (>=18 years) 2.Those presenting with any of the following: a. Clinical symptoms suggestive of COVID-19 (i.e. those who have at least one of the following symptoms: recent onset of i) new continuous cough and/or ii) high temperature) and/or iii) loss of, or change in, sense of smell or taste (anosmia) and /or b. Those with virologically confirmed SARS-CoV-2 infection and are admitted at the CFLTC or DH, Palakkad. 3. Provision of informed consent

Exclusion criteria

Exclusion criteria: 1. People 2. Inability to consent 3. Pregnancy 4. Immunosuppression 5. Inability to perform HSNIG 6. Those taking part in another interventional medical trial 7. Those without access to a supply of salt 8. Those who have had a negative COVID-19 swab result for the present symptoms 9. Those who opt for home isolation after testing Covid positive.

Design outcomes

Primary

MeasureTime frame
Self-reported time to resolution as assessed by completion of the validated self-reported, modified, short form of the Wisconsin Upper Respiratory Symptom Survey (WURSS-24), which will be used to collect daily symptom data.Timepoint: end of illness or 07 days

Secondary

MeasureTime frame
1. Severity of all symptoms 2. The length of time for individual symptoms to resolve 3. Severity of individual symptoms 4. Any variations in the routine blood investigations done during the course of stay in hospital. 5. Participants needing oxygen support/ developing hypoxia. 6. Length of stay in hospital 7. Number of participants reporting side effects of nasal irrigation 8. Types and severity of side effects reported 9. Extra cost incurred for the purpose of HSNIG Timepoint: end of illness or 07 days

Countries

India

Contacts

Public ContactDr V M Hemlata Katiyar

Govt Medical college (IIMS), Palakkad

hemayush@gmail.com9444124853

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026